Patent: 6,562,957
✉ Email this page to a colleague
Summary for Patent: 6,562,957
Title: | Genomic sequence encoding endoglin and fragments thereof |
Abstract: | A method of diagnosing hereditary haemorrhagic telangiectasia (HHT) which includes the steps of: obtaining a sample of genomic DNA from a patient or fetus; and determining whether the DNA contains a mutation in a gene encoding endoglin, betaglycan, TGF-.beta. type I receptor (RI), TGF-.beta. type II receptor (RII), or TGF-.beta./activin type I receptor (TSR-I), such a mutation being an indication that the patient or fetus bears a gene making the patient or fetus susceptible to HHT. |
Inventor(s): | Letarte; Michelle (Toronto, CA), Marchuk; Douglas A. (Chapel Hill, NC), McAllister; Kimberly (Durham, NC) |
Assignee: | HSC Research & Development Limited Partnership (CA) Duke University (Durham, NC) |
Application Number: | 09/506,859 |
Patent Claims: | see list of patent claims |
Details for Patent 6,562,957
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2014-11-29 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2014-11-29 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2014-11-29 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |